#United States #Carlsbad #Ourself #MI9™ #Brightening Serum

Ourself's Latest Innovation in Skincare

Ourself, a pioneering name in biotech beauty, has recently introduced its Complexion Brightening Serum, a product that promises to significantly reduce skin discoloration and prevent future pigmentation issues. Utilizing advanced technology, this serum stands out due to its patented MI9™ peptide and Tiered-Release Vesicle™ (TRV™) technology. With a strong focus on clinical effectiveness, this product is set to revolutionize the skincare market with its pioneering approach.

The MI9™ peptide is designed to tackle pigment formation right at the source while paired with tranexamic acid, ensuring deep absorption into the skin for optimal results. The TRV™ system enhances the efficacy of tranexamic acid, which is known for its challenging delivery properties due to its larger molecular structure. Clinical evidence backs the effectiveness of this new serum, showcasing significant results in minimizing discoloration.

Dr. Swati Kannan, a board-certified dermatologist associated with Ourself, commented on the challenges of treating skin discoloration. She noted that conditions such as UV exposure, inflammation, and hormonal changes can trigger discoloration, often leading to recurrence even after successful treatment. Ourself's innovative approach through the combination of MI9™ and TRV™ technologies is expected to provide swift and lasting results for individuals struggling with this issue.

Key Benefits and Results

The new serum's unique formulation delivers clinically validated outcomes, demonstrating remarkable effectiveness in various studies:

• - A 38% reduction in melanin was observed within just 14 days.
• - 68% of participants reported noticeable improvement in brown spots within two weeks.
• - A significant 87% of subjects saw improvements in overall skin discoloration.
• - Furthermore, every participant noted better skin smoothness by the end of the 12-week treatment period.

How It Works

The serum combines various key ingredients that synergistically address uneven skin tone:

• - MI9™ Peptide: Works at the melanocyte level to inhibit excess melanin production by binding to the MC1 receptor.
• - Tranexamic Acid (TXA): Deeply delivered through the TRV™ system to effectively reduce discoloration driven by inflammation.
• - Other beneficial components include 4-Butylresorcinol, which helps regulate enzyme activity responsible for pigment formation, Stabilized Vitamin C to combat oxidative stress, and Niacinamide to effectively reduce melanosome transfer.
• - Additionally, Retinyl Linoleate promotes cell turnover, further minimizing existing pigmentation issues.

Jim Hartman, CEO of Ourself, expressed his enthusiasm about the new launch, stating that the development of MI9™ reflects the company’s commitment to innovation. With the issuance of a new patent for this peptide, Ourself's total patent portfolio has grown to 21, showcasing its leadership in scientific advancements in the beauty industry.

Commitment to Innovation

Dr. Arisa Ortiz, another board-certified dermatologist and Ourself investigator, emphasized the breakthroughs encapsulated within the Complexion Brightening Serum. By merging MI9™ with the TRV™ delivery system, Ourself not only addresses the effectiveness of treatment but also matches the consumers' needs for quicker and effective results.

With its headquarters in Carlsbad, CA, Ourself is at the forefront of skincare technology, pioneering transformations in how active ingredients penetrate the skin, leading to a promising future for biotechnology in beauty. This latest serum is a significant step forward for consumers seeking effective solutions to persistent skin concerns. Ongoing clinical studies continue to reinforce the brand's mission, establishing a foundation of trust in a market hungry for authentic scientific advancements.